

Local time GMT-4		Wednesday 24th August, 2022
16:00 - 18:00	Registration (Hotel Best Western Premier Marina Las Condes)	
18:30 - 21:00	Welcome reception	
Local time GMT-4		Thursday 25th August, 2022
07:00 - 08:30	Registration (Hotel Best Western Premier Marina Las Condes)	
08:30 - 08:45	Welcome - Dr. Ignacio Sánchez - President of Pontificia Universidad Católica de Chile	
08:45 - 10:30	Session 1: Molecular mechanisms and phenotypes 1 Moderators: Carlos Bacino - Andreas Zankl	
08:45	ISDS-115, Lianlei Wang	Disruptions of <i>SOX9</i> K2 domain reduce protein stability and induce mild skeletal dysplasia and late-onset scoliosis
09:00	ISDS-17, Valerie Cormier-Daire	Biallelic variants in <i>SLC35B2</i> cause a novel chondrodysplasia with hypomyelinating leukodystrophy
09:15	ISDS-19, Guilherme Yamamoto	Rothmund-Thomson syndrome type I with growth hormone deficiency is associated with a not previously described gene in an autosomal recessive inheritance pattern in seven families
09:30	ISDS-114, Annette Madison	Clinical and molecular characterization of Chilean patients with X-linked hypophosphatemia
09:45	ISDS-61, Gretl Hendrickx	Heterozygous pathogenic variants in the <i>CBFB</i> gene cause a novel phenotype resembling cleidocranial dysplasia
10:00 - 10:30	ISDS-126, Andrea Superti-Furga	MutLands, a new advancement in the anatomic pathology of the human genome and in variant interpretation
10:30 - 11:00	Coffee break	
11:00 - 12:15	Session 2: Molecular mechanisms and phenotypes 2 Moderators: Valérie Cormier-Daire - Antonio Rossi	
11:00	ISDS-02, V. Reid Sutton	Quantitative phenotypic analyses of Robinow syndrome: WNT signalling perturbation and phenotypic similarities and variability
11:15	ISDS-16 Nathalia Liberatoscioli Menezes de Andrade	High prevalence of growth plate related genes in a cohort of children with isolated short stature
11:30	ISDS-25 Sarah Smithson	Rare genetic mechanisms in skeletal dysplasia solved by reanalysis of whole exome/genome data
11:45	ISDS-82 Lorenzo Botto	More than meets the eye: unsuspected systemic diseases identified through skeletal dysplasias.
12:00	ISDS-111, Andreas Zankl	Integrating the ISDS Nosology with the G2P Project and the MONDO Disease Ontology
12:15 - 12:45	David Rimoin lecture, Professor Matthew Warman	
13:00 - 14:00	Lunch	
14:00 - 14:20	Biomarin Corporate Symposium	
14:20 - 15:20	Session 3: focus on molecular diagnosis 1 Moderators: Karen Heath - Geert Mortier	
14:20	ISDS-68, Daniel Carvalho	TAR syndrome cohort of 20 Brazilian patients: variable clinical phenotype and molecular characterization of <i>FBMA</i> variants.
14:35	ISDS-76, Yiming Wang	Development of a Genetic Diagnostic Algorithm for Individuals with Split Hand Foot Malformation
14:50	ISDS-130, Carlos Bacino	Increasing the Diagnosis Rate in Rare Bone disorders. Our Experience in the Undiagnosed Disease Network at Baylor College of Medicine
15:05	ISDS-14, Alistair Calder	Eiken dysplasia with Parathyroid Hormone resistance: two new paediatric cases with the same novel variant
15:20	ISDS-41, Bruno Marcarini	Next-generation sequencing applied to skeletal disorders: a ten-year experience in a Tertiary Center in Brazil
15:35 - 15:50	Coffee break	
15:50 - 16:50	Poster session 1	
17:10	Social program - free evening	
Local time GMT-4		Friday 26th August, 2022
08:30 - 10:00	Session 4: clinical series and observations Moderators: Alistair Calder - Ravi Savarirayan	
08:30	ISDS-09, Sheela Nampoothiri	Skeletal Dysplasia Registry from a Tertiary Hospital from South India : 16 Years Experience
08:45	ISDS-35, Isabela Pasa	Molecular analysis of severe cases of Osteogenesis imperfecta and other rare low-mineral density disorders
09:00	ISDS-44, Maria Eduarda Gomes	Ancestry study in Brazilian patients with Cartilage Hair Hypoplasia syndrome with possible founder effect of the g.196C>T variant
09:15	ISDS-63, Cathleen Raggio (To be confirmed)	Should osteogenesis imperfecta be labeled as a low bone mass condition?
09:30	ISDS-13, Caroline Michot	Nine new cases of spondylometaphyseal dysplasia with corner fractures: enhancement of the phenotypic spectrum of <i>FN1</i> gene mutations
09:45	ISDS-52, Lucy Scrimshaw	Cerebral vasculopathy in osteopathia striata with cranial sclerosis, a rare but important complication.
10:00 - 10:45	Coffee break	
10:45 - 11:30	Session 5: skeletal dysplasias: prenatal aspects Moderators: Melita Irving - Denise Cavalcanti	
10:45	ISDS-43, Rhoda Akilapa	Observational study of fetal foramen magnum, thoracolumbar kyphosis and hippocampal development in Achondroplasia
11:00	ISDS-62, Catherine Gooch	Diagnostic challenges of fetal skeletal dysplasia: A cohort of patients with prenatal diagnoses of skeletal dysplasias with unique or atypical postnatal courses
11:15	ISDS-78, Nicole Nakousi-Capurro	A cohort of Brazilian OI patients with predominance of lethal phenotypes and analysis of the known recurrent mutations in Collagen 1 genes
11:30 - 12:00	Lecture on Nosology	
12:00 - 13:00	ISDS Business Meeting	
13:00 - 14:00	Lunch	
13:10 - 13:30	Takeda Corporate Lunch Symposium	
14:00 - 15:15	Session 6: Evaluation of growth, quality of life, pain and functionality Moderators: Roberto Mendoza - Jacqueline Hecht	
14:00	ISDS-54, Antonio Rossi	Identification of potential non-invasive biomarkers in diastrophic dysplasia
14:15	ISDS-66, Ximena Ortega	Diffusion-Tensor Imaging of the Physes: new technique to evaluate skeletal growth in patients with skeletal dysplasia
14:30	ISDS-42, Penelope Ireland	Development of the Screening Tool for Everyday Mobility and Symptoms (STEMS) for Skeletal Dysplasia
14:45	ISDS-70, Rosario Ramos Mejia	Evaluation of functionality-mobility in patients with skeletal dysplasias in Argentina: application of the STEMS (Screening Tool for Everyday Mobility and Symptoms)
15:00	ISDS-105, Natassja Billich	Nutritional issues in skeletal dysplasia: A scoping review
15:15 - 15:45	Coffee break	
15:45 - 17:00	Session 7: Biomarkers and mouse models Moderators: Matthew Warman - Caroline Michot	
15:45	ISDS-75, Jacqueline Hecht	Nutraceutical treatment strategies in a mouse model of pseudoachondroplasia
16:00	ISDS-48, Elvire Gouze	Lentiviral vector-based gene therapy for type II collagen disorders
16:15	ISDS-64, Pavel Krejci	Modelling achondroplasia in mouse to address the future therapy targets
16:30	ISDS-95, Laurence Legeai-Mallet	Hypochondroplasia gain-of-function mutation in <i>FGFR3</i> causes defective bone mineralization in mice
16:45	ISDS-20, Carl Dambkowski	Low-dose infliximab, an oral selective fibroblast growth factor receptor tyrosine kinase inhibitor, demonstrates activity in a preclinical model of hypochondroplasia
17:00 - 18:00	Poster session 2	
19:15 - 23:00	Conference dinner	
21:00	Maroteaux Award	
Local time GMT-4		Saturday 27th August, 2022
08:30 - 09:30	Patient family session	
09:45 - 11:15	Session 8: Clinical and observational studies Moderators: Debora Bertola - Lorenzo Botto	
09:45	ISDS-107, Ilian Arsof	Quantifying Outcomes in Fibrodysplasia Ossificans Progressiva (FOP) by Patient Age: Results from an International Burden of Illness Survey
10:00	ISDS-39, Melita Irving	ACHieve Study: Baseline Characteristics of a Multicenter Observational Study of Children with Achondroplasia
10:15	ISDS-10, David Tunkel	Otolaryngology Utilization in Patients with Achondroplasia: Results from the CLARITY Study
10:30	ISDS-28, Juan Ulerena Jr	Health-related quality of life (HRQoL) in achondroplasia: findings from LISA (Life Impact Study on Achondroplasia), a multinational and observational study in Latin America
10:45	ISDS-33, Ravi Savarirayan	Medical history of children enrolled in PROPEL: A prospective clinical assessment study in children with achondroplasia
11:00	ISDS-119, Julie Hoover-Fong	Mode of Delivery Influence on Surgical Morbidity in Fetuses with Achondroplasia from CLARITY (Achondroplasia Natural History Study)
11:15 - 11:35	Ipsen Corporate Symposium	
11:35 - 12:00	"FOP Clinical and molecular diagnosis, and genotype-phenotype correlation"	
11:35 - 12:00	Coffee break	
12:00 - 12:45	Session 9: Treatment Trials for Achondroplasia Moderators: Julie Hoover-Fong - Reid Sutton	
12:00	ISDS-49, Nadia Merchant	A Prospective Clinical Trial of Vosoritide in Hypochondroplasia: Baseline Demographics and Preliminary Results
12:15	ISDS-69, Ravi Savarirayan	A Randomized Controlled Trial of Vosoritide in Infants and Toddlers With Achondroplasia
12:30	ISDS-97, Melita Irving	Insights into the effects of vosoritide on the craniofacial structure of children with achondroplasia
12:45 - 13:00	ISDS Awards Ceremony - Organizing committee	
13:00 - 14:00	Closing remarks	
13:00 - 14:00	Lunch	